Recent studies have shown that inhibiting GSK-3β can reduce Nrf2 by nuclear export and degradation of Nrf2 in liver cancer cells and improve the rate of cell survival during the late phase of oxidative stress9, 10. The gene discussed is NFE2L2; the disease is liver cancer.